全文获取类型
收费全文 | 2129篇 |
免费 | 287篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 78篇 |
妇产科学 | 37篇 |
基础医学 | 137篇 |
口腔科学 | 81篇 |
临床医学 | 319篇 |
内科学 | 528篇 |
皮肤病学 | 40篇 |
神经病学 | 78篇 |
特种医学 | 304篇 |
外科学 | 244篇 |
综合类 | 45篇 |
预防医学 | 313篇 |
眼科学 | 38篇 |
药学 | 76篇 |
中国医学 | 1篇 |
肿瘤学 | 108篇 |
出版年
2023年 | 53篇 |
2022年 | 27篇 |
2021年 | 34篇 |
2020年 | 51篇 |
2019年 | 32篇 |
2018年 | 63篇 |
2017年 | 47篇 |
2016年 | 59篇 |
2015年 | 61篇 |
2014年 | 114篇 |
2013年 | 143篇 |
2012年 | 69篇 |
2011年 | 86篇 |
2010年 | 85篇 |
2009年 | 97篇 |
2008年 | 69篇 |
2007年 | 94篇 |
2006年 | 74篇 |
2005年 | 66篇 |
2004年 | 60篇 |
2003年 | 25篇 |
2002年 | 34篇 |
2001年 | 31篇 |
2000年 | 38篇 |
1999年 | 34篇 |
1998年 | 74篇 |
1997年 | 92篇 |
1996年 | 79篇 |
1995年 | 59篇 |
1994年 | 63篇 |
1993年 | 53篇 |
1992年 | 21篇 |
1991年 | 18篇 |
1990年 | 34篇 |
1989年 | 48篇 |
1988年 | 42篇 |
1987年 | 38篇 |
1986年 | 41篇 |
1985年 | 39篇 |
1984年 | 16篇 |
1983年 | 13篇 |
1982年 | 28篇 |
1981年 | 32篇 |
1980年 | 18篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1977年 | 14篇 |
1976年 | 15篇 |
1975年 | 13篇 |
1969年 | 5篇 |
排序方式: 共有2440条查询结果,搜索用时 15 毫秒
61.
Julia A. Woolgar FRCPath PhD Asterios Triantafyllou FRCPath PhD Alfio Ferlito MD DLO DPath FRCSEd ad hominem FRCS ad eundem FDSRCS ad eundem FHKCORL FRCPath FASCP IFCAP Kenneth O. Devaney MD JD FCAP James S. Lewis Jr MD FCAP Pieter J. Slootweg MD DMD PhD Leon Barnes MD FASCP FCAP 《Head & neck》2013,35(6):895-901
This is the first part of a 3‐part comprehensive review of intraosseous carcinoma of the jaws. We have outlined 4 groups of intraosseous carcinoma of the jaws (metastatic, salivary‐type, odontogenic, and primary intraosseous carcinoma), emphasizing the need for accurate diagnosis and the problems associated with changing classification systems, standardization of diagnostic criteria and nomenclature, and the accuracy of existing literature. In this first part, the features of metastatic and the very rare salivary‐type carcinomas of the jaws are examined with particular emphasis on histologic and immunohistochemical characteristics, diagnostic difficulties, and uncertainties. © 2012 Wiley Periodicals, Inc. Head Neck, 2012 相似文献
62.
63.
Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumour. Having a second or subsequent operation at recurrence may be a positive prognostic factor for survival. Recent studies suggest that socio-demographic variables may influence survival, raising the question whether surgical care differs based on these variables. We examined the relationship between selected socio-demographic variables and the number of repeat operations undergone by patients with recurrent GBM. Data from all patients diagnosed with GBM between 2001 and 2011 was obtained from a clinical database maintained across two institutions (one public, one private). The clinical and socio-demographic factors for patients who received one operation were compared to those who had two or more operations, using chi-squared analyses to determine statistical differences between groups. Socioeconomic status was measured using the Index of Relative Socioeconomic Advantage and Disadvantage scores. Of 553 patients, 449 (81%) had one operation and 104 (19%) had ?2 operations. Patients who had ?2 operations were significantly younger (median 55 years versus 64 years, p < 0.001), less likely to have multifocal (p = 0.043) or bilateral (p = 0.037) disease and more likely to have initial macroscopic resection (p = 0.006), than those who had only one operation. Socioeconomic status did not significantly differ between the groups (p = 0.31). Similarly, there was no significant difference between the number of operations in patients from regional versus city residence and public versus private hospital. This is reassuring as it suggests similar surgical management options are available for patients regardless of socio-demographic background. 相似文献
65.
66.
67.
68.
To optimally demonstrate the value of risk management, our actions must show the benefits. The American Society for Healthcare Risk Management (ASHRM) board needs to provide support through tools and resources. ASHRM members must show through their actions the value of risk management. And ASHRM members need to show the organization where actions and activities should be focused in the future. Actions show the value of enterprise risk management. 相似文献
69.
70.